Table 4.
Separate and joint effects of baseline CTCs and cfDNA on OS of progressing patients estimated through the Cox regression modeling.
| Baseline Biomarkers | Separate Effect | Joint Effect | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| CTCs | 0.160 | 0.144 | ||||
| ≤2 | 1.00 | (Ref.) | 1.00 | (Ref.) | ||
| >2 | 1.90 | 0.79–4.58 | 1.98 | 0.80–4.91 | ||
| cfDNA | 0.005 | 0.005 | ||||
| ≤836.5 | 1.00 | (Ref.) | 1.00 | (Ref.) | ||
| >836.5 | 4.00 | 1.54–10.40 | 4.08 | 1.55–10.72 | ||
HR: hazard ratio adjusted for age at start of nivolumab, gender, histotype, ECOG PS, smoking status, number of metastases, prior lines of treatment. 95% CI: 95% confidence intervals for HR. p-value: probability level associated with the likelihood ratio test. Ref.: reference category.